Clinical trials
Relapsed or Refractory Multiple Myeloma clinical trials
Below are recruiting relapsed or refractory multiple myeloma clinical trials, each written for real people, not researchers. We’re tracking 1,287 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07096700Recruiting
VR and wearable brace for multiple sclerosis rehabilitation
This trial tests whether combining virtual reality exercises with a leg brace can help people with multiple sclerosis improve their walking and balance. If you have mild to moderate disability and can use the Exoband brace, you may be eligible.
Bologna, BolognaAges 18–65 - NCT07114809Recruiting
Can brain stimulation and virtual reality boost thinking in MS?
This study tests whether a combination of gentle brain stimulation (tDCS) and virtual reality exercises can improve memory and thinking problems in people with multiple sclerosis. If you have mild to moderate disability and no major health issues, you may be able to join.
Genova, ItalyAges 18–65 - NCT07121322RecruitingPhase 2
Dornase Alfa and Cisplatin for resistant germ cell cancer
This trial tests a combination of two drugs, dornase alfa and cisplatin, for men with germ cell cancer that has not responded to standard treatments or has come back. The goal is to see if this new combination can shrink tumors or stop them from growing.
BratislavaAges 18 years+ - NCT07207148Recruiting
Ocrelizumab and weight-loss drugs for MS
This study looks at combining ocrelizumab (an MS treatment) with GLP-1 agonists (like Ozempic, used for weight management) in people with MS. It aims to see if the combination is safe and beneficial.
Chicago, IllinoisAges 18–70 - NCT07252895Recruiting
Testing the EXOPULSE Suit for walking in multiple sclerosis
This trial tests whether the EXOPULSE Suit can help people with multiple sclerosis walk better. You will try the suit and we will measure how it affects your walking over time.
BerckAges 18 years+ - NCT07303790RecruitingEarly Phase 1
Study of GC012F for people with multiple sclerosis
This early phase trial tests a new treatment called GC012F for people with multiple sclerosis. It aims to see how safe and tolerable it is, and may offer a new option for those whose current treatments are not working well enough.
Hubei, HubeiAges 18 years+ - NCT07304375Recruiting
Exercise and sleep effects on learning and abilities in MS
This trial tests how combining exercise and sleep monitoring can improve motor learning and daily function in people with early relapsing-remitting multiple sclerosis. It may help you move better and feel more capable in daily life.
CopenhagenAges 18–70 - NCT07320235RecruitingPhase 1
Combination treatment for relapsed AML
This trial tests a new combination of drugs for people whose acute myeloid leukemia (AML) has come back or not responded after at least one prior treatment, and who have no other standard options. The goal is to see if adding imetelstat to other therapies can help.
New York, New YorkAges 18 years+ - NCT07334301RecruitingPhase 1/Phase 2
Combination treatments for relapsed high-risk neuroblastoma
This trial is testing different combinations of medicines for children with high-risk neuroblastoma that has come back. It has two paths: one for children whose disease has relapsed only once, and another for those whose disease has come back more than once. The goal is to find which treatments work best.
SydneyAges 1 year+ - NCT07342777Recruiting
Exercise for Pain Relief in Multiple Sclerosis
This study tests whether exercise can help reduce pain in people with multiple sclerosis. If you have MS and moderate to severe pain, you may be asked to participate in a supervised exercise program.
Aarhus, DenmarkAges 18 years+ - NCT07497399RecruitingPhase 2
Testing a diabetes drug for weight loss in MS
This trial tests if a GLP-1 receptor agonist can help people with multiple sclerosis who have a high BMI. It may reduce inflammation and improve health.
Baltimore, MarylandAges 18–60 - NCT07366801RecruitingPhase 2/Phase 3
Preventing graft versus host disease in children with blood cancer
This trial tests if adding special immune cells (Treg cells) to a stem cell transplant from a half-matched donor can lower the risk of graft versus host disease (a serious side effect where donor cells attack the patient's body) in children and young adults with blood cancers.
MoscowAges 1–25 - NCT07388992Recruiting
Walking patterns in people with MS
This study uses special sensors to compare walking patterns in people with multiple sclerosis (MS) and healthy volunteers. The goal is to see how MS affects walking over time, which may lead to better ways to track and treat movement problems.
LilleAges 18–65 - NCT07389590RecruitingPhase 4
Switching MS drugs for wearing-off symptoms
This study tests whether switching from ocrelizumab to a similar drug, ublituximab, can help people with MS who experience 'wearing-off' symptoms before their next infusion. It may offer a new option to keep symptoms more stable between doses.
Baltimore, MarylandAges 18–65 - NCT01703429Recruiting
Alternative care program for people with multiple sclerosis
This study looks at how a complementary or alternative care approach affects people living with multiple sclerosis. It may help to understand whether this type of program improves symptoms or quality of life over time.
Kenmore, WashingtonAges 18–100 - NCT01371630RecruitingPhase 1/Phase 2
Inotuzumab plus chemotherapy for certain types of childhood-like leukemia
This early-phase trial studies how well a targeted drug (inotuzumab ozogamicin) combined with chemotherapy treats acute lymphoblastic leukemia (ALL). It may help people with newly diagnosed ALL who may not tolerate standard intensive chemotherapy, especially older adults.
Houston, TexasAges 18 years+ - NCT02433028Recruiting
Long-term study for MS and related nervous system conditions
This is a long-term hospital study that follows people diagnosed with MS (and a few related conditions) to understand how disease changes over time. You may be asked to have regular check-ups, brain scans, and provide blood samples so researchers can track disease and treatment effects.
Aarau, Canton of AargauAges Any age - NCT02784210RecruitingPhase 2
Steroid treatment to reduce inflammation in active MS lesions
This Phase 2 study tests whether corticosteroid medicine can reduce inflammation at the edge of active multiple sclerosis (MS) plaques seen on MRI. It may help calm “hot” areas in the brain where MS activity is happening.
Bethesda, MarylandAges 18–120 - NCT02115295RecruitingPhase 2
Venetoclax plus chemotherapy for AML, high-risk MDS, or blast CML
This trial tests a combination treatment (venetoclax plus several chemotherapy medicines) for people with AML, high-risk MDS, or CML that has progressed into a blast phase. It may help by killing leukemia-like blood cells and improving disease control.
Houston, TexasAges 18–65 - NCT02649985RecruitingPhase 1/Phase 2
PET brain scan study for several brain and mood conditions
This early-phase study uses PET and MRI brain scans to better understand brain changes in multiple sclerosis, Alzheimer’s disease, and other neurological or mood conditions. The goal is to test whether these scans can show disease-related differences and guide future treatments.
Boston, MassachusettsAges 18–85 - NCT02390752RecruitingPhase 1
Early drug study for children and young adults with hard-to-treat cancers
This Phase 1 trial tests pexidartinib (TURALIO) to see how safe it is and how well it works against refractory (hard-to-treat) leukemias and solid tumors, including tumors seen with NF1 and MPNST. It mainly helps researchers learn the best way to dose the medication and gather early signals of benefit.
Bethesda, MarylandAges 3–35 - NCT06675864RecruitingPhase 1/Phase 2
YTB323 for non-active progressive MS
This trial tests a new treatment called YTB323, which is a type of personalized cell therapy (CAR-T) designed to target your immune system and slow down MS progression. It is for people with non-active progressive MS who have seen their disability worsen recently.
Darlinghurst, New South WalesAges 18–60 - NCT07397975Recruiting
Using speech to predict relapse in psychosis
This study uses speech recordings from a smartphone app to see if changes in the way you talk can predict when someone might have a relapse of psychosis. It is for people who are currently stable or for healthy volunteers to compare.
KlecanyAges 18–65 - NCT07399262Recruiting
Music-based walking training for multiple sclerosis
This study tests whether walking to a steady beat of music can help improve your walking and balance. It is for people with mild to moderate multiple sclerosis who can walk but may need a little support.
Istanbul, ZeytinburnuAges 18–65
Hear when a new Relapsed or Refractory Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for relapsed or refractory multiple myeloma?
- Yes. Clin2 currently lists 1,287 recruiting relapsed or refractory multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a relapsed or refractory multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a relapsed or refractory multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.